<DOC>
	<DOC>NCT00943735</DOC>
	<brief_summary>The primary objective of the study is to assess the level of medication adherence observed among subjects receiving a specific combination of education and support materials (YourWay plan) along with a prescription for fesoterodine.</brief_summary>
	<brief_title>This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder</brief_title>
	<detailed_description>This is a non-interventional, observational study. Study investigators will recruit symptomatic, fesoterodine-naïve subjects when they present with OAB symptoms during regularly-scheduled physician visits fesoterodine-naïve subjects with OAB symptoms present during regularly-scheduled physician visits</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Male or female outpatients &gt;=18 years old Eligible for receiving Toviaz 4mg or 8mg QD treatment based on the approved US label. Female subjects who are pregnant, lactating, or who are intending to become pregnant within 28 days after the completion of the study (use of contraceptives is not required to participate in the study) Have participated in any other studies involving study drugs within 30 days prior to entry in the study Subjects who have previously taken fesoterodine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Overactive Bladder Incontinence Adherence Behavioral interventions</keyword>
</DOC>